A study in rats using a clinical-stage soluble guanylate cyclase (sGC) stimulator, praliciguat, highlights the role of sGC in the liver, particularly the presence of the sGC-cGMP pathway in two liver cell types but not in hepatocytes, and finds that stimulation of sGC can inhibit inflammation, fibrosis, and steatosis; the results suggest that praliciguat may represent a potential therapy for nonalcoholic steatohepatitis.
Article #18-21045: "sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH," by Katherine C. Hall et al.
MEDIA CONTACT: Jessi Rennekamp, Cyclerion Therapeutics, Cambridge, MA; tel: 857-338-3319, 952-649-8600; e-mail: jrennekamp@cyclerion.com
###
Proceedings of the National Academy of Sciences